Ruxolitinib Phosphate Patent Expiration

Ruxolitinib Phosphate is used for treating conditions such as myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. It was first introduced by Incyte Corp in its drug Jakafi on Nov 16, 2011. Another drug containing Ruxolitinib Phosphate is Opzelura.


Ruxolitinib Phosphate Patents

Given below is the list of patents protecting Ruxolitinib Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Opzelura US11602536 Topical treatment of vitiligo by a JAK inhibitor May 05, 2041 Incyte Corp
Opzelura US11510923 Ruxolitinib formulation for reduction of itch in atopic dermatitis Sep 04, 2040 Incyte Corp
Opzelura US11590137 Ruxolitinib formulation for reduction of itch in atopic dermatitis Sep 04, 2040 Incyte Corp
Opzelura US11590138 Topical treatment of vitiligo by a jak inhibitor Jun 10, 2040 Incyte Corp
Opzelura US10758543

(Pediatric)

Topical formulation for a JAK inhibitor Nov 20, 2031 Incyte Corp
Opzelura US10869870

(Pediatric)

Topical formulation for a JAK inhibitor Nov 20, 2031 Incyte Corp
Opzelura US11219624

(Pediatric)

Topical formulation for a JAK inhibitor Nov 20, 2031 Incyte Corp
Opzelura US10758543 Topical formulation for a JAK inhibitor May 20, 2031 Incyte Corp
Opzelura US10869870 Topical formulation for a JAK inhibitor May 20, 2031 Incyte Corp
Opzelura US11219624 Topical formulation for a JAK inhibitor May 20, 2031 Incyte Corp
Opzelura US11571425 Topical formulation for a JAK inhibitor May 20, 2031 Incyte Corp
Opzelura US11590136 Topical formulation for a JAK inhibitor May 20, 2031 Incyte Corp
Jakafi US10016429

(Pediatric)

Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Jakafi US8722693

(Pediatric)

Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Jakafi US8822481

(Pediatric)

Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Jakafi US8829013

(Pediatric)

Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Opzelura US10610530

(Pediatric)

Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Opzelura US8722693

(Pediatric)

Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Opzelura US8822481

(Pediatric)

Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Dec 12, 2028 Incyte Corp
Jakafi US7598257

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Jun 24, 2028 Incyte Corp
Jakafi US8415362

(Pediatric)

Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Jun 24, 2028 Incyte Corp
Opzelura US7598257

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Jun 24, 2028 Incyte Corp
Opzelura US8415362

(Pediatric)

Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Jun 24, 2028 Incyte Corp
Jakafi US10016429 Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Jakafi US8722693 Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Jakafi US8822481 Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Jakafi US8829013 Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Opzelura US10610530 Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Opzelura US8722693 Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Opzelura US8822481 Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile Jun 12, 2028 Incyte Corp
Jakafi US7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Dec 24, 2027 Incyte Corp
Jakafi US8415362 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Dec 24, 2027 Incyte Corp
Opzelura US7598257 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors Dec 24, 2027 Incyte Corp
Opzelura US8415362 Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Dec 24, 2027 Incyte Corp
Jakafi US9079912

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Jun 12, 2027 Incyte Corp
Jakafi US9814722

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Jun 12, 2027 Incyte Corp
Opzelura US10639310

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Jun 12, 2027 Incyte Corp
Opzelura US9079912

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Jun 12, 2027 Incyte Corp
Opzelura US9974790

(Pediatric)

Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Jun 12, 2027 Incyte Corp
Jakafi US9079912 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Dec 12, 2026 Incyte Corp
Jakafi US9662335 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec 12, 2026 Incyte Corp
Jakafi US9814722 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec 12, 2026 Incyte Corp
Opzelura US10639310 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors Dec 12, 2026 Incyte Corp
Opzelura US9079912 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors Dec 12, 2026 Incyte Corp
Opzelura US9974790 Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors Dec 12, 2026 Incyte Corp



Ruxolitinib Phosphate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List